Join us with our Guest, Synthetic Biologics’ Joseph Sliman, MD, MPH, Chief Medical Officer, as we discuss the Company’s novel microbiome-focused product candidates. Protection and preservation of the natural gut microbiome continues to be a key role in the prevention of certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel disease (IBS). Synthetic Biologics is developing two lead microbiome-focused drugs poised for Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain common
|